利用斑马鱼来筛选抗血管小分子药物


近日,EXPERIMENTAL AND THERAPEUTIC MEDICINE (Exp Ther Med) 杂志发表了上海第九人民医院副院长、心内科主任王长谦课题组的研究成果“Identification of mundoserone by zebrafish in vivo screening as a natural product with anti-angiogenic activity”。该研究利用斑马鱼模型筛选了来自Natural Products Collection of MicroSource的具有抗血管生成潜力的天然产物,并首次发现Mundoserone作为抗血管小分子的治疗前景。


该案例涉及的斑马鱼研究工作,全部在南模斑马鱼平台上完成。


天然产物一直是国外制药巨头进行新药研发的重要源头之一。据 Newman 和 Cragg(2007)统计,在1981 年 1 月至 2006 年 6 月全世界批准上市的 1184 个新化学实体药物中,有 52% 来源于天然产物或与天然产物有关。

 

利用血管转基因斑马鱼通过活体高通量筛选技术、斑马鱼独有的表型分析技术、以及药物作用信号通路分析等,南模生物与上海第九人民医院副院长、心内科主任王长谦课题组合作,成功的从美国天然产物库中筛选到4个全新的抗血管小分子,而Mundoserone这种小分子便是其中之一。

 

  • Mundoserone抑制斑马鱼中ISV的形成

利用fli1a:EGFP转基因斑马鱼评估Natural Products Collection of MicroSource中240种天然产物的抗血管生成活性。在受精后24小时,用文库化合物处理胚胎24小时,然后使用荧光显微镜评估节间血管(ISV)的形态,然后计数ISV并计算抑制率。


结果发现,Mundoserone抑制了ISV和DLAV的形成(图1),而且Mundoserone的抗血管生成作用是具有剂量依赖性的(图2)。在10μM浓度下观察到显着的抗血管生成活性,导致ISV抑制率为73.6±1.3%。

图片1.png

Figure 1. Among the natural products screened in Tg(fli1a: EGFP)y1 zebrafish, mundoserone was identified as an anti‑angiogenic compound. Representative (A‑C) bright‑field and (D‑F) fluorescent images of zebrafish embryos at 24 h post‑fertilization treated with 0.1% dimethyl sulfoxide (control), 10 µM mundoserone or 5 µM PTK787 (positive control) for 24 h (magnification, x40). (G‑I) Magnification of images (D‑F) (magnification, x112.5). Compared with those in the control group, embryos treated with mundoserone presented with a lower number of incomplete ISVs and only occasional sprouts (asterisks) of the DA were observed. (J) Chemical structure of mundoserone. DLAV, dorsal longitudinal anastomotic vessels; ISVs, intersegmental vessels; DA, dorsal aorta; PCV, posterior cardinalvein.


图片2.png

Figure 2. Mundoserone inhibits the trunk angiogenesis of zebrafish in a dosedependent manner. Representative (AE) bright field and (FJ) fluorescent images of zebrafish embryos at 24 h postfertilization treated with 0.1% dimethyl sulfoxide (control), mundoserone (2.5, 5 or 10 µM) or 5 µM PTK787 (positive control) for 24 h (magnification, x40). (KO) Magnification of images FJ (magnification, x112.5). Compared with the control, embryos exposed to mundoserone exhibited a lower number of incomplete ISVs and only occasional sprouts (asterisks) of the DA were observed. Quantification of (P) the number of complete ISVs and (Q) inhibition rate in mundoserone-treated embryos. Values are expressed as the mean ± standard error of the mean (n=10).

 

  • Mundoserone通过下调SLIT3/ROBO1和FGFR/PTP-RB以及上调NOTCH1A来发挥抗血管生成作用

通过RT-qPCR分析血管生成相关基因的表达。结果表明,Mundoserone显著降低SLIT3,ROBO1,ROBO2,FGFR2,FGFR3和PTP-RB的表达,但增加了NOTCH1A的表达(图3)。COX2, SLIT2, ROBO4, DLL4, HEY2以及EFNB2的表达没有变化。由此推测Mundoserone有效的血管生成抑制活性可能是通过下调SLIT / ROBO1和FGFR / PTP-RB以及NOTCH1A信号传导的上调来起作用的(图4)。

图片3.png

Figure 3. Expression of angiogenesis‑associated genesin zebrafish embryos after treatment with 10 µM mundoserone. Values are expressed asthe mean ± standard error of the mean (n=4). *P<0.05 vs. Control. FGFR, fibroblast growth factor receptor; SLIT3, slit guidance ligand 3; ROBO, roundabout guidance receptor; PTP-RB, protein tyrosine phosphatase, receptor type B; DLL, deltalike ligand 4; COX, cyclooxygenase; VEGFR, vascular endothelial growth factor receptor; PIK3R2, phosphoinositide-3-kinase regulatory subunit 2; HEY2, hes related family bHLH transcription factor with YRPW motif 2; EFNB2, ephrin B2.

图片4.png

Figure 4. Schematic model illustrating the mechanism of action of mundoserone on angiogenesis.FGFR, fibroblast growth factor receptor; SLIT3, slit guidance ligand 3; ROBO, roundabout guidance receptor; PTP‑RB, protein tyrosine phosphatase, receptor type B; VE‑PTP, vascular endothelial cell‑specific phosphotyrosine phosphatase.

 

Mundoserone作为抗血管小分子的首次发现,对于将来开发治疗血管新生相关的疾病(如肿瘤、糖尿病视网膜病、血管瘤、牛皮癣、类风湿性关节炎、月经失调等)提供一种全新的治疗选择。


你也可能感兴趣

Tamoxifen诱导Cre-ERT2小鼠 使用指南

Cre-ERT2在无Tamoxifen诱导的情况下,在细胞质内处于无活性状态;当Tamoxifen诱导后,Tamoxifen的代谢产物4-OHT(雌激素类似物)与ERT结合,可使Cre-ERT2进核发挥Cre重组酶活性。

查看
【小鼠大学问】基因工程小鼠的命名规则

常见的基因工程小鼠可以分为两种命名方式,包括基因定点修饰的小鼠命名,比如:敲除、敲入、点突变等等,和随机转基因的小鼠命名。

查看